Boron neutron capture therapy for head and neck cancer: Relevance of nuclear-cytoplasmic volume ratio and anti-tumor effect. -A preliminary report.
(10)B
ABE factor
BNCT
CBE factor
Head and neck cancer
N/C ratio
Journal
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine
ISSN: 1872-9800
Titre abrégé: Appl Radiat Isot
Pays: England
ID NLM: 9306253
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
05
08
2019
revised:
23
03
2020
accepted:
29
04
2020
entrez:
21
6
2020
pubmed:
21
6
2020
medline:
11
8
2021
Statut:
ppublish
Résumé
BNCT is a type of particle beam radiation therapy that utilizes an α particle and 7Li nucleus generated when a thermal neutron is captured by a 10B nucleus involved in the boron compound that has been taken up into tumor tissue selectively. In this report, the relevance of N/C ratio of tumor cell and anti-tumor effect for BNCT clinical cases of head and neck cancer were verified. Examination of pre-irradiated tumor histopathological specimens of 9 BNCT treated head and neck cancer patients (4 CR patients, 5 non-CR patients) was performed. The statistically significant difference between the CR group and the non-CR group was examined for the physical dose was multiplied by the absolute biological effectiveness (ABE) value determined from the patient's tumor specific N/C ratio. Analysis showed the mean tumor dose could not distinguish between CR and non-CR groups. However, the ABE dose could clearly distinguish between the CR group and the non-CR group (p = 0.0250). The N/C ratio of tumor cell can influence the anti-tumor effect of BNCT for HNC.
Identifiants
pubmed: 32561048
pii: S0969-8043(20)30341-9
doi: 10.1016/j.apradiso.2020.109212
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
109212Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest None to declare. Kawasaki Medical School IRB approval number 40, 110.